F16.251
BillableHallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is F16.251 an HCC code?
Yes. F16.251 maps to Drug/Alcohol Psychosis under the CMS-HCC V28 risk adjustment model (and Drug/Alcohol Psychosis under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for F16.251
For F16.251 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed F16.251 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
F16.251 is the ICD-10-CM diagnosis code for hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations. A person dependent on hallucinogenic drugs is experiencing psychosis with hallucinations (seeing or hearing things that aren't real) caused by the hallucinogen use. F16.251 sits in the ICD-10-CM chapter for mental, behavioral and neurodevelopmental disorders (f01-f99), within the section covering mental and behavioral disorders due to psychoactive substance use (f10-f19).
Under the CMS-HCC V28 risk adjustment model, F16.251 maps to Drug/Alcohol Psychosis (HCC 135) with a community, non-dual, aged base RAF weight of 0.000. Under the older V24 model, F16.251 mapped to the same category but with a base RAF weight of 0.434 — V28 recalibrated weights across the entire model. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
This code specifies that hallucinations are present; use F16.259 if psychosis is present without specifying hallucinations. Because F16.251 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for F16.251 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •This code specifies that hallucinations are present; use F16.259 if psychosis is present without specifying hallucinations
- •Document the type of hallucinations (visual, auditory, tactile) and their relationship to hallucinogen use
Clinical Significance
Hallucinogen dependence with psychotic disorder featuring hallucinations captures active perceptual disturbances (visual, auditory, or tactile) caused by hallucinogen dependence. This can persist as hallucinogen persisting psychosis and requires psychiatric evaluation, possible antipsychotic therapy, and safety precautions.
Documentation Requirements
- ✓Documentation of hallucinogen dependence
- ✓Specific documentation of hallucinations (visual, auditory, or other sensory modalities)
- ✓Provider statement that hallucinations are induced by hallucinogen use
- ✓Mental status examination documenting hallucination type and content
- ✓Distinction from hallucinogen persisting perception disorder (flashbacks, F16.283) which is a separate condition
- ✓Assessment of insight — does the patient recognize hallucinations as substance-induced?